SCHEMBL5202652

SCHEMBL5202652

O=S(=O)(NCC1CCC(c2nc(-c3cccc(Cl)c3)c[nH]2)CC1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.51
VCP P55072 2/20 0.45
NPY5R Q15761 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 1/20 0.42
PKM P14618 1/20 0.42
FBP1 P09467 1/20 0.41
STK4 Q13043 1/20 0.41
STK3 Q13188 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
PARG Q86W56 1/20 0.39
GPR39 O43194 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
KAT6A Q92794 1/20 0.39
NAT1 P18440 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5206599 0.86 GBA1 (0.48) GBA1VCPNPY5RMEN1KMT2A
SCHEMBL5207428 0.78 VCP (0.43) VCPSTK4STK3
SCHEMBL5207254 0.78 STK4 (0.42) VCPSTK4STK3
SCHEMBL5209916 0.77 KMT2A (0.46) GBA1VCPNPY5RKMT2AALDH1A1
SCHEMBL5204794 0.77 KMT2A (0.46) GBA1VCPNPY5RKMT2AALDH1A1
SCHEMBL5204673 0.75 VCP (0.46) VCP
SCHEMBL14609071 0.75 GBA1 (0.49) GBA1VCPNPY5RMEN1KMT2A
SCHEMBL90906 0.73 HSD11B1 (0.39) STK4STK3
SCHEMBL27776222 0.72 GABRA1 (0.46) HTR1AHTR7
SCHEMBL2470122 0.71 GBA1 (1.00) GBA1MEN1KMT2AALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
WO-2003104255-A2 SUBSTITUTED 2-CYCLOHEXYL-4-PHENYL-1H-IMIDAZOLE DERIVATIVES NEUROGEN CORPORATION (US) 2003-12-18 WO disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R GBA1 3318/4885VCP 3862/4885NPY5R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.